Macugen pegaptanib: Phase IV data

In the prospective, open-label Phase IV LEVEL trial in 568 patients, maintenance therapy with 0.3 mg intravitreal Macugen every 6 weeks for 48 weeks preserved mean visual acuity of 61.8 letters at wee...